Franziska Duckstein
Overview
Explore the profile of Franziska Duckstein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
43
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Infante F, Lomazi E, Zagoya C, Duckstein F, Magro D, Pessotto F, et al.
J Pediatr (Rio J)
. 2024 Aug;
101(1):82-88.
PMID: 39134095
Objective: Translating and cross-culturally adapting the CFAbd-Score, Cystic Fibrosis (CF) Abdominal Score, to use in Brazilian spoken Portuguese. The CFAbd-Score is a questionnaire for assessing CF-related abdominal symptoms and their...
2.
Mainz J, Duckstein F, Zagoya C, Koitschev A
J Cyst Fibros
. 2024 Apr;
23(2):183-184.
PMID: 38604889
No abstract available.
3.
Tabori H, Barucha A, Zagoya C, Duckstein F, Dunay G, Sadrieh P, et al.
J Clin Med
. 2024 Mar;
13(6).
PMID: 38541878
(1) Background: The introduction of highly effective CFTR-modulating therapies (HEMT) has changed the course of the disease for many people with Cystic Fibrosis (pwCF). Attention previously focused on life-threatening conditions...
4.
Mainz J, Barucha A, Huang P, Bechinger L, Duckstein F, Polte L, et al.
Front Pharmacol
. 2023 Nov;
14:1167407.
PMID: 38026920
Elexacaftor-tezacaftor-ivacaftor (ETI) is a novel, highly effective CFTR modulator combination proven to enhance lung function and body weight in people with cystic fibrosis (pwCF) carrying a F508del mutation. Recently, we...
5.
Mainz J, Lester K, Elnazir B, Williamson M, McKone E, Cox D, et al.
J Cyst Fibros
. 2023 Oct;
23(3):474-480.
PMID: 37806792
Background: RECOVER is a multicentre post-approval study of Elexacaftor/Tezacaftor/Ivacaftor (ETI) in pwCF in Ireland and the UK. The CFAbd-Score is the first validated CF-specific patient reported outcome measure (PROM) focusing...
6.
Mainz J, Zagoya C, Polte L, Naehrlich L, Sasse L, Eickmeier O, et al.
Front Pharmacol
. 2023 May;
14:1207356.
PMID: 37205908
[This corrects the article DOI: 10.3389/fphar.2022.877118.].
7.
Erdmann N, Schilling T, Hentschel J, Lehmann T, von Bismarck P, Ankermann T, et al.
Front Immunol
. 2022 Dec;
13:947359.
PMID: 36466839
Background: In cystic fibrosis (CF), acute respiratory exacerbations critically enhance pulmonary destruction. Since these mainly occur outside regular appointments, they remain unexplored. We previously elaborated a protocol for home-based upper...
8.
Barucha A, Mauch R, Duckstein F, Zagoya C, Mainz J
Expert Rev Respir Med
. 2022 Jul;
16(7):723-735.
PMID: 35853615
Introduction: Airway infection with pathogens and its associated pulmonary exacerbations (PEX) are the major causes of morbidity and premature death in cystic fibrosis (CF). Preventing or postponing chronic infections requires...
9.
Mainz J, Zagoya C, Polte L, Naehrlich L, Sasse L, Eickmeier O, et al.
Front Pharmacol
. 2022 Jun;
13:877118.
PMID: 35721187
The novel and highly effective CFTR modulator combination of elexacaftor-tezacaftor-ivacaftor (ETI) has been shown to improve lung function and body weight in people with Cystic Fibrosis (pwCF) carrying a F508del...
10.
Stefano M, Sandy N, Zagoya C, Duckstein F, Ribeiro A, Mainz J, et al.
J Cyst Fibros
. 2021 Sep;
21(3):497-501.
PMID: 34511390
No abstract available.